Restoration on MSN11d
RARE Japanese Lighter Restoration - Sarome Blue Bird Rocket Car
Watch an astonishing transformation as this rare Blue Bird Rocket Car lighter undergoes a complete restoration! Layers of ...
BioPharma Dive2d
2seventy bio, Bluebird’s cell therapy spinout, sells to Bristol Myers for less than $300M
The deal ends 2Seventy’s short run as an independent company, during which it restructured, sold off research and lost nearly ...
BioSpace1d
Bluebird’s Go-Private Deal Highlights Fraught Life Preserver for Struggling Biotechs
Facing declining valuations and funding challenges, public biotechs like bluebird bio are going private to restructure, ...
BioSpace7d
Rare Disease Biotechs Left in a Lurch as Congress Fails To Renew Priority Review Program
Congress did not reauthorize the rare pediatric disease priority review program at the end of 2024. Advocates say the ripple ...
STAT13d
Turbulence at the FDA & bluebird Bio’s sale
FDA reform needs to be underpinned by strategy, not ‘indiscriminate’ cuts The Trump administration could save the lives of ...
Shropshire Star11d
A rare beauty, isn't she? Muscular, too, with enough horsepower to knock your socks off.
In the 1920s and 1930s national heroes were the breed who sought glory by pushing the boundaries on land, water, and in the ...
GEN19d
StockWatch: Bluebird Bio Plunges on Buyout, as Gene Therapy’s Woes Grow
Meek was elected chairman of rare disease drug developer Swedish Orphan Biovitrum (Sobi) in December. In Bluebird’s statement announcing the buyout, Meek said the planned investment by Carlyle ...
Express & Star11d
A rare beauty, isn't she? Muscular, too, with enough horsepower to knock your socks off.
Thanks to some rare pictures in our archive we can chart ... had reached 231.44mph in the Golden Arrow at Daytona Beach. Bluebird under tow during the ill-fated trip to Verneuk Pan in 1929.
MedCity News21d
Cash-Strapped Gene Therapy Firm Bluebird Bio Agrees to Acquisition by Private Equity
Bluebird Bio, a company that steered three gene ... The 2022 FDA approvals of Zynteglo, for the rare blood disorder beta thalassemia, and Skysona, for the ultra-rare neurological disease cerebral ...
The Boston Globe21d
Struggling Somerville biotech Bluebird Bio to be sold for less than $30 million
Bluebird Bio announced Friday it would sell ... showcased both the power of modern genetic medicine to deliver cures for devastating rare diseases and the profound challenges any company would ...